Cardiol Therapeutics Company Description

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.

Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure.

It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Cardiol Therapeutics Inc.

Country	Canada
Founded	2017
Industry	Biological Products, Except Diagnostic Substances
Employees	18
CEO	David Elsley

Contact Details

Address: 2265 Upper Middle Road East Oakville, Ontario L6H 0G5 Canada
Phone	289 910 0850
Website	cardiolrx.com

Stock Details

Ticker Symbol	CT9
Exchange	Frankfurt Stock Exchange
Share Class	Class A Shares
Fiscal Year	January - December
Reporting Currency	CAD
SIC Code	2836

Key Executives

Name	Position
David Elsley	Chief Executive Officer
Christopher Waddick	Chief Financial Officer
Bernard Lim	Chief Operating Officer
Trevor Burns	Head of Investor Relations